Research map: The Multiple Criteria Qualitative Value‐Based Pricing Framework “ MARIE ” for Novel Cell and Gene Therapy

Back to the article

Papers in this map

  1. Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] · Darius Lakdawalla · 2018 · 549 citations · Cited by this paper
  2. Fecal Microbiota Transplantation and Microbiota‐Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions · 2026 · Related
  3. Implementation of Value-based Pricing for Medicines · Claudio Jommi · 2019 · 87 citations · Cited by this paper
  4. Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure · 2026 · Related
  5. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective · Richard B. Lipton · 2018 · 65 citations · Cited by this paper
  6. ASCPT News · 2026 · Related
  7. Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey · Lisa T. Belter · 2020 · 55 citations · Cited by this paper
  8. Reframing the Landscape for Achieving Equitable Pharmacotherapy Health Outcomes: Introducing Pharmacogenequity · 2026 · Related
  9. Projecting the long‐term societal value of a disease‐modifying treatment for Alzheimer's disease in the United States · María Prados · 2022 · 42 citations · Cited by this paper
  10. In This Issue · 2026 · Related
  11. Direct and indirect costs of families with a child with acute lymphoblastic leukaemia in an academic hospital in China: a cross-sectional survey · Yijiong Ren · 2019 · 24 citations · Cited by this paper
  12. From Non‐Cancer Pain to Cancer Survivorship: Applying Opioid Deprescribing Lessons across the Divide · 2026 · Related
  13. Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease · Frida Schain · 2020 · 21 citations · Cited by this paper
  14. Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study · 2026 · Related
  15. Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma · Robert M. Rifkin · 2019 · 19 citations · Cited by this paper
  16. Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation · 2026 · Related
  17. The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies · Siyu Ma · 2022 · 16 citations · Cited by this paper
  18. Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2 / MATE ‐Mediated Renal Drug‐Drug Interactions in Healthy Volunteers · 2026 · Related
  19. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France · Michaël Mounié · 2019 · 11 citations · Cited by this paper
  20. Statins Safety Signals: From Precautions to Proportionate Evidence‐Based Labeling · 2026 · Related
  21. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland · Arjun Bhadhuri · 2022 · 7 citations · Cited by this paper
  22. Cost of illness of leukemia in Japan – Trend analysis and future projections · Rebeka Amin · 2018 · 6 citations · Cited by this paper
  23. Value of Anti–Vascular Endothelial Growth Factor Gene Therapy for Neovascular Age-Related Macular Degeneration · Sean T. Berkowitz · 2020 · 6 citations · Cited by this paper
  24. Multiple criteria qualitative value-based pricing framework “MARIE” for new drugs · Akina Takami · 2024 · 6 citations · Cited by this paper

Source: OpenAlex (CC0)